Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03218761 · ClinicalTrials.gov registry record
POTS NET mRNA Functional Correlation With NET Activity
A clinical trial of Postural Tachycardia Syndrome, sponsored by Vanderbilt University Medical Center.
- Active
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT03218761 is a study of Postural Tachycardia Syndrome that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 200 participants, above the 72-participant average among 19 other Postural Tachycardia Syndrome trials with a reported enrollment target (178% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03218761, a study of Postural Tachycardia Syndrome, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
DNA Acetylation can be responsible for significant down-regulation of transcription of the Norepinephrine Transporter (NET). NET is an important clearance transporter that removes norepinephrine (NE) from sympathetic neuronal synapses. Very low levels of NET can "cause" Postural Tachycardia Syndrome (POTS) or make these patients more susceptible to certain medications. Quantified NET messenger RNA (mRNA) levels from a peripheral blood sample may be able to assess NET availability, which is simpler than older methods. This has not been validated against NET function. In this protocol, the investigators seek to assess whether these NET mRNA levels correlate with NET function. The investigators will assess the DHPG (NET dependent NE metabolite):NE ratio in POTS patients and control subjects from both plasma and urine samples.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST NET mRNA level
- DIAGNOSTIC_TEST Plasma catechols
- DIAGNOSTIC_TEST Urine Catechols
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2017-07-14 |
| Est. Completion | 2029-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03218761
The ClinicalTrials.gov registry entry for NCT03218761 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 72-participant average among 19 other Postural Tachycardia Syndrome trials with a reported enrollment target (178% higher). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Postural Tachycardia Syndrome appearing as the primary indexed condition, and to 3 interventions - of which NET mRNA level is the first listed.
NCT03218761 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT03218761 about?
NCT03218761 is a clinical study titled "POTS NET mRNA Functional Correlation With NET Activity". DNA Acetylation can be responsible for significant down-regulation of transcription of the Norepinephrine Transporter (NET). NET is an important clearance transporter that removes norepinephrine (NE) from sympathetic neuronal synapses. Very low levels of NET can "cause" Postural Tachycardia Syndrome...
What is the current status of trial NCT03218761?
This trial is currently active not recruiting. The enrollment target is 200 participants. The study started on 2017-07-14. Estimated completion is 2029-12-31.
What conditions does trial NCT03218761 study?
This clinical trial studies the following conditions: Postural Tachycardia Syndrome.
What interventions are being tested in trial NCT03218761?
The interventions under investigation include: NET mRNA level (DIAGNOSTIC_TEST), Plasma catechols (DIAGNOSTIC_TEST), Urine Catechols (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03218761?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03218761 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postural Tachycardia Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Periaqueductal Gray-vagus Nerve Interface Malfunction Explain the Natural History With Its Numerous Co-morbidities?
RECRUITING · NA
-
Inappropriate Sinus Tachycardia Registry
RECRUITING
-
Autoimmune Basis for Postural Tachycardia Syndrome
RECRUITING · NA
-
A Study of Pyridostigmine in Postural Tachycardia Syndrome
RECRUITING · Phase 2
-
Intravenous (IV) Saline and Exercise in Postural Tachycardia Syndrome (POTS)
ACTIVE NOT RECRUITING · NA
-
Acute Salt Handling in Orthostatic Intolerance
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.